Profile of fluticasone furoate/vilanterol dry powder inhaler combination therapy as a potential treatment for COPD.

ABSTRACT: Currently, there is no cure for chronic obstructive pulmonary disease (COPD). The limited efficacy of current therapies for COPD indicates a pressing need to develop new treatments to prevent the progression of the disease, which consumes a significant amount of health care resources and is an important cause of mortality worldwide. Current national and international guidelines for the management of stable COPD patients recommend the use of inhaled long-acting bronchodilators, inhaled corticosteroids, and their combination for maintenance treatment of moderate to severe stable COPD. Once-daily fluticasone furoate/vilanterol dry powder inhaler combination therapy has recently been approved by the US Food and Drug Administration and the European Medicines Agency as a new regular treatment fo

SUBMITTER: Caramori G 

PROVIDER: S-EPMC3940640 | biostudies-literature | 2014

REPOSITORIES: biostudies-literature